Pharmena S.A.

Warsaw Stock Exchange PHR.WA

Pharmena S.A. Operating Cash Flow for the year ending December 31, 2023: USD 8.38 M

Pharmena S.A. Operating Cash Flow is USD 8.38 M for the year ending December 31, 2023, a 1,917.63% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Pharmena S.A. Operating Cash Flow for the year ending December 31, 2022 was USD 415.17 K, a 152.04% change year over year.
  • Pharmena S.A. Operating Cash Flow for the year ending December 31, 2021 was USD -797.80 K, a -32.85% change year over year.
  • Pharmena S.A. Operating Cash Flow for the year ending December 31, 2020 was USD -600.52 K, a 82.64% change year over year.
  • Pharmena S.A. Operating Cash Flow for the year ending December 31, 2019 was USD -3.46 M, a -458.66% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
SV Wall Street
Warsaw Stock Exchange: PHR.WA

Pharmena S.A.

CEO Mr. Konrad Palka
IPO Date Aug. 1, 2008
Location Poland
Headquarters ul. Wólczanska 178
Employees 15
Sector Consumers Staples
Industries
Personal Care Biotechnology Cosmetics Perfumes & Fragrances Pet Food Pharmaceuticals Plastics Tobacco
Description

Pharmena S.A., a biotechnology company, manufactures and sells active ingredients in various areas of medicines in Poland and internationally. The company offers dermatological cosmetics, including skin, hair, and nail care products, as well as dietary supplement for atherosclerosis prophylaxis. It offers its products under the Menavitin, Dermena, Allerco, and Thermi names. The company is developing 1-MNA, an anti-atherosclerosis drug which is under phase II clinical trial. Pharmena S.A. was founded in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.

StockViz Staff

February 6, 2025

Any question? Send us an email